The U.S. Food and Drug Administration (FDA) has approved a new device to treat pancreatic cancer in adults. Called Optune Pax, it was developed by Novocure. This portable, non-invasive device delivers electrical fields to the abdomen, which help stop cancer cells from growing by disrupting their rapid division. It does this without harming healthy tissue.
The FDA’s approval shows its commitment to supporting safe and effective medical devices that help treat long-term diseases and improve people’s lives. This approval is also part of the FDA’s initiative to create devices that fit easily into patients' daily lives at home.
The device works with special adhesive patches that are placed on the skin. These patches are connected to an electric field generator. The treatment settings are preset by the manufacturer and can't be changed by the patient or doctor. Patients are trained on how to use the device, including how to charge it, replace the battery, position the patches, and replace parts of the device twice a week. The device is worn with the generator in a small bag, allowing patients to continue their daily activities while receiving treatment.
Executive Statement
According to FDA Commissioner Marty Makary, M.D., M.P.H., having treated many patients with pancreatic cancer, he know how difficult the diagnosis can be. The pancreatic cancer community deserves better therapeutic options. The FDA is working tirelessly to bring potentially promising therapies to people who need them.
